Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.56 |
| ▸ | MDM4 | O15151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378041 | 0.93 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30055375 | 0.93 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL1486199 | 0.93 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL378040 | 0.93 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29367388 | 0.93 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29352428 | 0.93 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30988971 | 0.88 | MDM4 (0.54) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30549389 | 0.88 | MDM4 (0.54) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL31297461 | 0.88 | MDM4 (0.54) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30656568 | 0.86 | MDM4 (0.59) | CASP3MDM4TP53KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097744-A2 | DNA-COMPATIBLE WITTIG OLEFINATION OF ON-DNA PEPTIDYL-YLIDES FOR DEVELOPMENT OF ON-DNA PEPTIDOMIMETICS THROUGH DIVERSITY-ORIENTED SYNTHESIS (DOS) | THE ROCKEFELLER UNIVERSITY (US) | 2024-05-10 | — | — | WO | disclosed |